

## SUPPLEMENTARY TABLES

Supplementary Table 1. Oligonucleotides sequences.

Experiment	Name	Position or orientation	Sequence (5'-3')
Luciferase construction		R: 95~ 77	TCCGCTCGAG GATTCCCCCGTCAGTCAC(XhoI)
	SUZ12	L: SUZ12p1-WT -91~ -84	F: 5' - GGGGTACCA <b><i>TTTT</i></b> CCCGCGAATTCAGTT (Kpn I) -3'
		L: SUZ12p2-WT -1395 ~ -1388	F: 5' - GGGGTACC AGGCTTCAG <b><i>GAAGT</i></b> CTGAGAA (Kpn I) -3'
		R: 271~ 251	TCCGCTCGAG CAAAGTCACGCGGCTAATAA (XhoI)
	CCDC43	L: CCDC43p1-WT -737~ -714	F: 5' - GGGGTACC TTGTTTGT <b><i>TTTT</i></b> GAGAC <b><i>GGAA</i></b> TTT (Kpn I) -3'
		L: CCDC43p2-WT -1389 ~ -1369	F: 5'- GGGGTACC GAAGCCTTCCTGG <b><i>ATTTC</i></b> CT (Kpn I) -3'
Site-directed mutagenesis	SUZ12	L: SUZ12p1-MT -91~ -84	F: <b><i>ACTGTA</i></b> CCGCGAATTCAGTTAA
		L: SUZ12p2-MT -1395 ~ -1388	F: AGGCTTCAG <b><i>TACGG</i></b> CTGAGAA
		L: SUZ12p3-MT -91~ -84 and -1395 ~ -1388	F: <b><i>ACTGTA</i></b> CCGCGAATTCAGTTAA and AGGCTTCAG <b><i>TACGG</i></b> CTGAGAA
		L: CCDC43p1-MT -737~ -714	F: TTGTTTGT <b><i>TTTT</i></b> GAGAC <b><i>GTAGTCT</i></b>
	CCDC43	L: CCDC43p2-MT -1389 ~ -1369	F: GAAGCCTTCCTGG <b><i>GTCTCT</i></b>
		L: CCDC43p3-MT -737~ -714and -1389 ~ -1369	F: TTGTTTGT <b><i>TTTT</i></b> GAGAC <b><i>GTAGTCT</i></b> and GAAGCCTTCCTGG <b><i>GTCTCT</i></b>
Chip		L: -179~ -155	CTAAGGATCTAGACTCGCTAAACC
	SUZ12	R: 92 ~ 77	GATTCCCCCGTCAGTCAC
		L:-1477 ~ -1457	GTGCCCAAGAGCTTAACAG
		R:- 1296~ -1272	CAGGCACTGCTAACACTACTATGA
		L: -757~ -737	CCTGGCTTTTGTGTTGTTG
	CCDC43	R: -564 ~ -544	GGAGAACCCCGTCTCTACT
	L:-1404 ~ -1384	CATCATCTCCACTGGGAAGC	
	R:- 1228~ -1204	TTTTTAATCCATTAGGAACAGACA	

\*Bold and *italic*: HMGA1 binding sites; underline: mutated *nucleotide* residues.

**Supplementary Table 2. Correlation between HMGA1 protein expression and the clinicopathological parameters of gastric carcinoma.**

Features	Total number (n=51)	HMGA1 expression		P
		Low	High	
Age (years)				
<60	30	10(33.3%)	20(66.7%)	0.249
>60	21	11(52.4%)	10(47.6%)	
Gender				
Male	34	15(44.1%)	19(55.9%)	0.764
Female	17	6(35.3%)	11(64.7%)	
Differentiation				
Well	11	8(72.7%)	3(27.3%)	0.028
Moderate	16	7(43.8%)	9(56.2%)	
Poor	24	6(25.0%)	18(75.0%)	
Lymph node metastasis				
Yes	36	10(27.8%)	26(72.2%)	0.004
No	15	11(73.3%)	4(26.7%)	
Tumor size(cm <sup>3</sup> )				
<5	27	16(59.3%)	11(40.7%)	0.009
≥ 5	24	5(20.8%)	19(79.2%)	
AJCC stage				
T1,T2	11	8(72.7.6%)	3(27.3%)	0.035
T3,T4	40	13(32.5%)	27(67.5%)	
AJCC TNM stage				
I II	16	12(75.0%)	4(25.0%)	0.002
III IV	35	9(25.7%)	26(74.3%)	